SCHEMBL24167686

SCHEMBL24167686

CC(c1ccc(N)cc1)c1ccn2ncnc2c1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.33
TGFBR1 P36897 1/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
ALDH1A1 P00352 1/20 0.33
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33
RAB9A P51151 1/20 0.33
KMT2A Q03164 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MAP4K4 O95819 2/20 0.32
PIK3CD O00329 1/20 0.32
DPP4 P27487 2/20 0.32
DPP7 Q9UHL4 2/20 0.32
KCNH2 Q12809 1/20 0.32
MAPK1 P28482 1/20 0.31
BACE1 P56817 1/20 0.31
HSD11B1 P28845 1/20 0.31
KIT P10721 1/20 0.30
MET P08581 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL902674 0.82 TGFBR1 (0.37) DYRK1ATGFBR1ALDH1A1MAP4K4PIK3CD
SCHEMBL24167382 0.80 EGFR (0.50) MAPT
SCHEMBL26751201 0.80 TGFBR1 (0.36) DYRK1ATGFBR1MAP4K4PIK3CDDPP4
Hydrochloric Acid SCHEMBL31123021 0.78 TGFBR1 (0.35) DYRK1ATGFBR1MAP4K4PIK3CDDPP4
SCHEMBL25335507 0.76 MAPK1 (0.36) DYRK1ATGFBR1ALDH1A1MAP4K4PIK3CD
SCHEMBL23691885 0.74 TGFBR1 (0.34) TGFBR1MAP4K4PIK3CDMAPK1HSD11B1
SCHEMBL25529726 0.74 TGFBR1 (0.37) TGFBR1ALDH1A1MAP4K4PIK3CDMAPK1
SCHEMBL24167687 0.73 EGLN2 (0.44) MAP4K4
SCHEMBL25574192 0.73 TGFBR1 (0.36) TGFBR1MAP4K4PIK3CDMAPK1HSD11B1
Hydrochloric Acid SCHEMBL22123553 0.72 DYRK1A (0.41) DYRK1ATGFBR1MAPTMAP4K4PIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265098-A1 ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 ENLIVEN INC. 2023-08-24 US disclosed
US-20230265098-A1 ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 ENLIVEN INC. 2023-08-24 US disclosed
WO-2022006386-A1 ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 ENLIVEN THERAPEUTICS, INC. (US) 2022-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265098-A1 ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 ERBB2, ERBB3, CHEK2 DYRK1A 638/4885TGFBR1 2704/4885MEN1 1307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.